Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Appointed director
IMPAX LABORATORIES INC (IPXL) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/01/2018 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Fourth Quarter and Full Year 2017 Results ‒ Q4 2017 Total Revenues of $183 Million; GAAP Net Loss Per Share of $4.18; Non-GAAP Adjusted Income Per Share of $0.11 ‒ ‒ Full Year 2017 Total Revenues of $776 Million; GAAP Net Loss Per Share of $6.53; Non-GAAP Adjusted Income Per Share of $0.63 ‒ ‒ Completes Operational and Cost Improvement Plans ‒ ‒ Combination with Amneal Pharmaceuticals Expected to Close in the Second Quarter of 2018 &#8210",
"Presentation"
11/09/2017 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Third Quarter 2017 Results ‒ Total Revenues of $206 Million; GAAP Loss Per Share of $0.69; Non-GAAP Adjusted Income Per Share of $0.23 ‒ ‒ Significant Progress on Operational and Cost Improvement Plans ‒ ‒ Company Announces Positive Results from Phase 2b Study of IPX203 ‒ ‒ Company Narrows Full Year 2017 Guidance &#8210",
"Presentation"
08/09/2017 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Solid Second Quarter 2017 Results with Total Revenues Increasing 17% to $202 Million ‒ GAAP Loss Per Share of $0.28; Non-GAAP Adjusted Income Per Share of $0.18 ‒ ‒ Generics Division Revenues Increase 24% to $151 Million ‒ ‒ Significant Progress on Operational and Cost Improvement Plans ‒ ‒ Company Reaffirms Full Year 2017 EPS Guidance &#8210",
"Presentation"
05/10/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/09/2016 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Second Quarter 2016 Financial Results — Second Quarter 2016 Revenue of $173 Million — — GAAP Loss Per Share of $0.04 and Adjusted Diluted EPS of $0.21— — Company Updates Full Year 2016 Financial Guidance — — Company Announces Positive Results from Phase 2a Study of IPX203 as a Potential Treatment for Parkinson’s Disease",
"Presentation"
05/10/2016 8-K Form 8-K - Current report
02/22/2016 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Fourth Quarter and Full Year 2015 Financial Results ● Fourth Quarter 2015 Revenues Increased 115% to $282 Million ● Fourth Quarter 2015 Adjusted Diluted EPS Increased to $0.62 and GAAP Diluted EPS Increased to $0.16 ● Full Year 2015 Revenues Increased 44% to $860 Million ● Full Year 2015 Adjusted Diluted EPS Increased to $1.45 and GAAP Diluted EPS Decreased to $0.54 ● Provides 2016 Financial Guidance",
"Presentation"
11/09/2015 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Third Quarter 2015 Financial Results — Revenues Increased 40% to $221 Million — — Adjusted Diluted EPS Increased 21% to $0.40 — — GAAP Diluted EPS Increased 123% to $0.49",
"Presentation"
08/10/2015 8-K Investor presentation, Quarterly results
Docs: "Impax Reports Second Quarter 2015 Financial Results — Impax Revenues Increased 14% to $214 Million in Second Quarter 2015 — — Adjusted Diluted EPS of $0.34; GAAP Net Loss of $0.03 Per Diluted Share— — Announced Sale of Daraprim ® for $55 Million — — Company Updates Full Year 2015 Financial Guidance",
"Presentation"
05/11/2015 8-K Quarterly results
Docs: "Impax Reports First Quarter 2015 Financial Results — Impax Revenues Increased 21% to $143 Million in First Quarter 2015 — — Tower Holdings Acquisition Closed; Incremental Synergies of $10 Million Identified — — U.S. Approval and Launch of RYTARY® — — Company Reaffirms Full Year 2015 Financial Guidance"
11/04/2014 8-K Quarterly results
Docs: "Impax’s Third Quarter 2014 Revenues Increased 19% to $158 Million — Third Quarter 2014 Adjusted Diluted EPS Increased to $0.33; GAAP Diluted EPS Increased to $0.22 — — Nine Month 2014 Revenues Increased 13% to $465 Million — — Company Updates 2014 Financial Guidance"
08/06/2014 8-K Quarterly results
Docs: "Impax’s Second Quarter 2014 Revenues Increased 45% to $188.1 Million ● Second Quarter 2014 Adjusted Diluted EPS Increased to $0.60; GAAP Diluted EPS Increased to $0.50 ● Company Updates 2014 Financial Guidance"
05/01/2014 8-K Quarterly results
Docs: "Impax Laboratories Reports First Quarter 2014 Results FDA Accepts RYTARY TM NDA Resubmission; Sets PDUFA Date of October 9, 2014"
11/04/2013 8-K Form 8-K - Current report
08/08/2013 8-K Form 8-K - Current report
05/01/2013 8-K Form 8-K - Current report
10/30/2012 8-K Form 8-K - Current report
07/31/2012 8-K Form 8-K - Current report
05/01/2012 8-K Form 8-K - Current report
02/28/2012 8-K Form 8-K - Current report
11/01/2011 8-K Form 8-K - Current report
08/02/2011 8-K Form 8-K - Current report
05/03/2011 8-K Form 8-K - Current report
02/24/2011 8-K Form 8-K - Current report
11/02/2010 8-K Form 8-K - Current report
08/03/2010 8-K Form 8-K - Current report
05/04/2010 8-K Form 8-K - Current report
02/25/2010 8-K Form 8-K - Current report
11/03/2009 8-K Form 8-K - Current report
08/04/2009 8-K Form 8-K - Current report
05/05/2009 8-K Form 8-K - Current report
02/26/2009 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy